Literature DB >> 33033390

Association between neonatal intensive care unit medication safety practices, adverse events, and death.

Laura E Miller1, Chris DeRienzo2, P Brian Smith1,3, Carl Bose4, Reese H Clark5, C Michael Cotten1, Daniel K Benjamin6, Chi D Hornik1,3, Rachel G Greenberg7,8.   

Abstract

OBJECTIVE: Determine the associations between neonatal intensive care unit (NICU) medication safety practices, laboratory-based adverse events (lab-AEs), and death. STUDY
DESIGN: We combined data from a 2016 survey of Pediatrix NICUs on use of medication safety practices with 2014-2016 infant data. We grouped NICUs based on the number of safety practices used (≤5, 6-7, and 8-10) and evaluated the association between the number of safety practices used and lab-AEs and deaths using logistic regressions.
RESULTS: Of the 94 NICUs included, 17% used ≤5 medication safety practices, 51% used 6-7, and 32% used 8-10. NICUs with more safety practices did not have a difference in lab-AEs or death.
CONCLUSION: In this cohort, the use of more medication safety practices was not associated with fewer lab-AEs or decreased death.
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2020        PMID: 33033390     DOI: 10.1038/s41372-020-00857-y

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  38 in total

Review 1.  Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature.

Authors:  Indra Chedoe; Harry A Molendijk; Suzanne T A M Dittrich; Frank G A Jansman; Johannes W Harting; Jacobus R B J Brouwers; Katja Taxis
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Reported adverse drug events in infants and children under 2 years of age.

Authors:  Thomas J Moore; Sheila R Weiss; Sigal Kaplan; Carol J Blaisdell
Journal:  Pediatrics       Date:  2002-11       Impact factor: 7.124

3.  Effectiveness of a barcode medication administration system in reducing preventable adverse drug events in a neonatal intensive care unit: a prospective cohort study.

Authors:  Frank H Morriss; Paul W Abramowitz; Steven P Nelson; Gary Milavetz; Stacy L Michael; Sara N Gordon; Jane F Pendergast; E Francis Cook
Journal:  J Pediatr       Date:  2008-09-27       Impact factor: 4.406

4.  Voluntary anonymous reporting of medical errors for neonatal intensive care.

Authors:  Gautham Suresh; Jeffrey D Horbar; Paul Plsek; James Gray; William H Edwards; Patricia H Shiono; Robert Ursprung; Julianne Nickerson; Jerold F Lucey; Donald Goldmann
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

Review 5.  Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Authors:  Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

6.  Impact of computerized physician order entry on clinical practice in a newborn intensive care unit.

Authors:  Leandro Cordero; Lynn Kuehn; Rajee R Kumar; Hagop S Mekhjian
Journal:  J Perinatol       Date:  2004-02       Impact factor: 2.521

7.  Medication safety in neonatal care: a review of medication errors among neonates.

Authors:  Natalia Krzyzaniak; Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2016-04-01

8.  NICU medication errors: identifying a risk profile for medication errors in the neonatal intensive care unit.

Authors:  T A Stavroudis; A D Shore; L Morlock; R W Hicks; D Bundy; M R Miller
Journal:  J Perinatol       Date:  2009-12-31       Impact factor: 2.521

9.  Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study.

Authors:  Desireé L Kunac; Julia Kennedy; Nicola Austin; David Reith
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 10.  A systematic review of observational studies evaluating costs of adverse drug reactions.

Authors:  Francisco Batel Marques; Ana Penedones; Diogo Mendes; Carlos Alves
Journal:  Clinicoecon Outcomes Res       Date:  2016-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.